FDA approves Lilly’s Mounjaro (tirzepatide) injection

The US Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide), Eli Lilly and Company’s new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) injection, to be used as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes.

Recent clinical trials ALSO found that, while not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators. “The approval of Mounjaro is an exciting step forward for people living with Type 2 diabetes, given the results seen in these clinical trials,” said Juan Pablo Frías, M.D., Medical Director, National Research Institute.

Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to be made available in the US in the coming weeks

To read more, CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags